



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

09/556,178

04/20/2000

Olga Bandman

PF-0417-2-DIV

5936

22428 7590 01/13/2011

FOLEY AND LARDNER LLP
SUITE 500
3000 K STREET NW
WASHINGTON, DC 20007

EXAMINER

STRZELECKA, TERESA E

ART UNIT

PAPER NUMBER

1637

MAIL DATE

DELIVERY MODE

01/13/2011

PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

<i>Examiner-Initiated Interview Summary</i>	Application No. 09/556,178	Applicant(s) BANDMAN ET AL.	
	Examiner TERESA E. STRZELECKA	Art Unit 1637	

All Participants:

(1) Teresa Strzelecka.

(2) Stephanie Vavra.

Date of Interview: 17 December 2010

Type of Interview:
☒ Telephonic
☐ Video Conference
☐ Personal (Copy given to: ☐ Applicant ☐ Applicant's representative)
Exhibit Shown or Demonstrated: ☐ Yes ☐ No
If Yes, provide a brief description: _____

Status of Application: Pending

(3) _____

(4) _____

Time: _____

Part I.

Rejection(s) discussed:

Claims discussed:

Prior art documents discussed:

Part II.

SUBSTANCE OF INTERVIEW DESCRIBING THE GENERAL NATURE OF WHAT WAS DISCUSSED:

Ms. Vavra was informed that the results of sequence search for SEQ ID NO: 3 and 5 revealed no sequences identical to SEQ ID NO: 3 and two sequences 99.5% and 99.2% identical to SEQ ID NO: 5. Examiner proposed that the following sequences are allowable: amino acid sequences comprising at least 98% identity to SEQ ID NO: 1, amino acid sequences comprising 98% identity to SEQ ID NO: 3 and amino acid sequences comprising SEQ ID NO: 5. The limitations of claim 1 drawn to sequences with at least 90% identity to any of the SEQ ID NOs, or to their biologically-active fragments or immunogenic fragments will need to be deleted, as they present written description and/or utility issues. Ms. Vavra is going to contact Applicant with the proposed claim amendments.

Part III.

☐ It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview directly resulted in the allowance of the application. The examiner will provide a written summary of the substance of the interview in the Notice of Allowability.

☐ It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview did not result in resolution of all issues. A brief summary by the examiner appears in Part II above.

/Teresa E Strzelecka/
Primary Examiner, Art Unit 1637
December 17, 2010

(Applicant/Applicant's Representative Signature – if appropriate)